☒ Petition for three (3) month(s) extension of time pursuant to 37 C.F.R. §§ 1.17 and 1.136(a). $460.00 for the extension of time.

☐ No fee is required.

☒ Check(s) in the amount of $532.00 is(are) enclosed.

☐ Please charge Deposit Account No. 02-2448 in the amount of $0.00. This form is submitted in triplicate.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. §§1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By _____
Leonard R. Svensson, #30,330

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

LRS/KR/clh
0459-0461P

Attachment

(Rev. 09/27/01)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope to: Commissioner of Patents and Trademarks, Washington D.C. 20231 on: 8-12-02
(Date of deposit)

BIRCH, STEWART, KOLASCH & BIRCH, LLP

_____
(Signature)

August 12, 2002
(Date of Signature)

c2 9. (Amended) A pharmaceutical composition according to claim 8, wherein the pharmaceutical composition is formulated as a fluid, ointment, gel, liniment, emulsion or spray (e.g. aerosol).

c2 17. (Amended) A method for treating hypersensitivity or inflammation in a mammal, characterised by administering a composition comprising

an extract or concentrate of Butyrospermum parkii comprising at least 5% (w/w) of a Butyrospermum-triterpene fraction such that said composition comprises at least 5 % w/w of said Butyrospermum-triterpene fraction,

said Butyrospermum-triterpene fraction comprises:
- at least 2% (w/w) lupeol;
- at least 2% (w/w) α-amyrin and/or β-amyrin; and
- at least 2% (w/w) butyrospermol;

wherein said triterpenes may be in the form of free alcohols or esters thereof.

18. (Amended) The method according to claim 17, wherein the treating of hypersensitivity or inflammation is for the treating of hypersensitivity of the skin or mucous membranes of a mammal.

Please add the following new claims:

c3 26. (New) The method according to claim 1, further comprising a pharmaceutically acceptable carrier.

27. (New) The method according to claim 1, further comprising at least 1% germanicol, dammaradienol, 24-methylene-dammarenol and/or parkeol,

Subj D1 28. (New) The method according to claim 1, wherein said esters are selected from the group consisiting of cinnamic acid esters, acetic acid esters and fatty acid esters.

29. (New) The method according to claim 2, further comprising 2-30% germanicol, dammaradienol, 24-methylene-dammarenol and/or parkeol,

30 (New) The method according to claim 3, wherein said esters are selected from the group consisiting of cinnamic acid esters, acetic acid esters and fatty acid esters.